Comparative therapeutic efficacy of clinafloxacin in leucopenic mice.
A cyclophosphamide-induced leucopenic mouse model was used to compare the therapeutic efficacy of clinafloxacin, a fluoroquinolone in clinical trials, with that of ciprofloxacin and imipenem/cilastatin, two clinically relevant standard drugs. Acute systemic infections induced by Escherichia coli, Pseudomonas aeruginosa, a penicillin-resistant Staphylococcus aureus and a methicillin-resistant S. aureus (MRSA) were used to evaluate drug efficacy. Median protective values (PD50) with 95% confidence limits were determined in both leucopenic and normal mice. Results show that clinafloxacin is potentially a useful agent in the treatment of neutropenic patients.
Shapiro
M A
MA
Department of Infectious Diseases, Parke-Davis Pharmaceutical Research, Ann Arbor, MI 48105, USA.
Dever
J A
JA
Sesnie
J C
JC
VanderRoest
S R
SR
D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002939:Ciprofloxacin / Q000627:therapeutic use; D005260:Female; D024841:Fluoroquinolones; D007970:Leukopenia / Q000188:drug therapy*; D016106:Methicillin Resistance; D051379:Mice; D015363:Quinolones / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013203:Staphylococcal Infections / Q000188:drug therapy
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D002939:Ciprofloxacin; C057477:clinafloxacin